Q1 2024 EPS Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Lowered by Analyst

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2024 EPS estimates for Intra-Cellular Therapies in a research note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of ($0.48) for the quarter, […]

Leave a Reply

Your email address will not be published.

Previous post Research Analysts Offer Predictions for CoreCivic, Inc.’s Q2 2024 Earnings (NYSE:CXW)
Next post Q2 2025 EPS Estimates for ReNew Energy Global Plc Decreased by Roth Capital (NASDAQ:RNW)